TMCnet News
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual MeetingBOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will deliver presentations of two abstracts showcasing progress of its clinical program evaluating ulixacaltamide for adults with essential tremor (ET) at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place in Denver, Colorado, April 13 – 18, 2024. “With Essential3, we’ve developed a decentralized trial program unlike any other in ET, and among the first in the industry,” said Marcio Souza, president and chief executive officer of Praxis. “The experiences of patients with ET are often overlooked so we designed a trial that removes typical obstacles to participation and concentrates on endpoints that truly matter. In our earlier Phase 2 Essential1 study, we observed that patients who were already on propranolol experienced additional benefits when adding ulixacaltamide. Our findings and learnings to date highlight the promise of ulixacaltamide for those living with ET.” Praxis at AAN 2024 | Colorado Convention Center Connect with members of our team at booth #1834 or head to one of our presentations listed below where we will share updates on our journey to develop a new ET therapy. P3003: An Innovative Multi-Study Phase 3 Program to Evaluate the Efficacy and Safety of Ulixacaltamide: The Future of Clinical Trial Design in Essential Tremor A poster presentation showcasing Praxis’ novel registrational study design
Emerging Neurologic Care Industry Presentation: Essential3: An Innovative, Decentralized Phase 3 Essential Tremor Program An industry platform presentation highlighting updates on Praxis’ Phase 3 registrational program
S30.010: Assessing Clinically Meaningful Improvement Associated with Ulixacaltamide Treatment in Adults with Essential Tremor on Concomitant Propranolol: Findings from Essential1 An oral presentation demonstrating potential benefit of ulixacaltamide over propranolol
Selected materials will be made available on the Resources page of Praxis’ website following presentation at AAN 2024: https://praxismedicines.com/resources/. About Ulixacaltamide About Praxis Forward-Looking Statements The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical trials; the expected timing of clinical trials, data readouts and the results thereof, and submissions for regulatory approval or review by governmental authorities; regulatory approvals to conduct trials; and other risks concerning Praxis’ programs and operations as described in its Annual Report on Form 10-K for the year ended December 31, 2023 and other filings made with the Securities and Exchange Commission. Although Praxis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on information and factors currently known by Praxis. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Investor Contact: Praxis Precision Medicines [email protected] 857-702-9452 Media Contact Ché Knight LifeSci Communications [email protected] 713-582-0681 |